Zocor Diabetes Risk?
Zocor lawsuits may soon be filed on behalf of people who develop diabetes while using the popular cholesterol drug.
Statins linked to diabetes
Last month, the Journal of the American Medical Association (JAMA) published a study that found people using high dose statins were 12 percent more likely to develop diabetes than people who use lower doses of drugs such as Lipitor, Crestor, Vytorin and Zocor. The study corroborates previous research that found that some statins increase the risk of diabetes by as much as one-third.
More than 25 million Americans suffer from type 2 diabetes, a chronic disease that can lead to a host of health problems including blurred vision, erectile dysfunction, increased appetite and fatigue. Millions of Americans take statins every year. Zocor (simvastatin) is the most popular statin; it is the only statin to be available in generic form.
Recent FDA announcement spotlight harmful Zocor side effects
Some forms of Zocor might be the most dangerous of all available statins. In June, the Food and Drug Administration issued a health warning over 80 mg Zocor after it was found to put users at a high risk of muscle damage and rhabdomyolysis – a sometimes-fatal kidney disorder. No new prescriptions of 80 mg Zocor will be issued, and current users of that dosage have been encouraged to talk to a physician about safer alternatives.
Medical concerns prompt Zocor lawsuit inquiries and hopes for settlement dicsussions
Zocor lawsuits for myopathy and muscle damage are currently being evaluated by Zocor lawyers across the United States. The first trial for Zocor muscle injury could take place in 2012. A new warning about a statin diabetes risk, particularly a Zocor diabetes risk, could mean that Zocor lawsuits will soon be given the go-ahead to proceed through US courts.
Zocor settlements could soon follow for people injured by the drug. Zocor lawyers estimate Zocor settlements could be worth a significant amount, depending on the severity of the victim’s injuries. Zocor lawyers are currently evaluating the claims of people who used the drug to determine if litigation is the appropriate course of action.